Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2005
03/31/2005US20050070709 dealkylation of a benzodioxane aniline in presence of chloroethanol
03/31/2005US20050070706 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070606 Pharmaceutical agent for mitochondrial disorders
03/31/2005US20050070591 Indole derivative
03/31/2005US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
03/31/2005US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders
03/31/2005US20050070577 Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
03/31/2005US20050070574 Novel compounds
03/31/2005US20050070572 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies
03/31/2005US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors
03/31/2005US20050070566 Imidazoquinoline derivatives
03/31/2005US20050070559 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
03/31/2005US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions
03/31/2005US20050070555 Aroyl pyridinones
03/31/2005US20050070544 Such as 7-chloro-4-hydroxy-2-[3-(3-chlorophenyl)prop-2-ynyl]-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione; binds NMDA receptor glycine site
03/31/2005US20050070539 Such as 1-(4-{4-[2-(cyclopropylmethyl-amino)-5-nitro-benzoyl]-piperazin-1-yl}-3-fluoro- phenyl)-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease
03/31/2005US20050070537 Use of dihydroimidazolones for the treatment of dogs
03/31/2005US20050070535 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070534 Non-peptidic NPY Y2 receptor inhibitors
03/31/2005US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder
03/31/2005US20050070530 Dipeptidyl peptidase inhibitors
03/31/2005US20050070521 Alkyl ether derivatives or salts thereof
03/31/2005US20050070517 Oxazol/thiazol-derivatives activators of the hppar-alpha receptor
03/31/2005US20050070493 Methods and compositions for treating Parkinson's disease
03/31/2005US20050070483 Subunit of a calcium channel; 3-[(2-Amino-4-methyl-pentanoylamino)-methyl]-5-methyl-octanoic acid for example or corresponding 1,5-diazocane-2,6-diones; treating drug addiction, pain and various mood disorders including depression and bipolar disorder; bioavailability
03/31/2005US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
03/31/2005US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor
03/31/2005US20050069980 Transport protein for use as tool in altering in vivo pharmacokinetics of a pharmaceutical, toxic substance or xenobiotics by modulating an ability to transport acidic amino acids; antitumor agents
03/31/2005US20050069943 101 human secreted proteins
03/31/2005US20050069878 Proteins associated with cell growth, differentiation, and death
03/31/2005US20050069877 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders
03/31/2005US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders.
03/31/2005US20050069598 Antidiabetic agents; moderate glucagon-like peptide; phosphoenolpyruvate carboxykinase inhbitors; weight control
03/31/2005US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
03/31/2005US20050069557 A protein neuroglobin derived from neuronal tissue; binging, storage oxygen; therapy for central nervous system disorders
03/31/2005US20050069547 Binding protein; therapy for bone tumors
03/31/2005US20050069541 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
03/31/2005US20050069537 Stimulants of survival of cells; binding of cellular adhesion molecular; prevent apoptosis
03/31/2005US20050069520 Methods and compositions for treating mammalian nerve tissue injuries
03/31/2005US20050069492 As neuroprotective agents in the therapy of neuronal disorders of the central and peripheral nervous systems
03/31/2005DE10340260A1 Mittel und Verfahren zur Behandlung und Prävention von TSE, sowie Verfahren zur Herstellung des Mittels Compositions and methods for treatment and prevention of TSE, and to processes for the preparation of the agent
03/31/2005CA2551037A1 Novel piperidine derivative
03/31/2005CA2540407A1 Compositions and methods using same for treating amyloid-associated diseases
03/31/2005CA2539566A1 Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors
03/31/2005CA2538789A1 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors
03/31/2005CA2538590A1 Novel gamma secretase inhibitors
03/31/2005CA2538381A1 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
03/31/2005CA2537916A1 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
03/31/2005CA2537094A1 Novel adenosine a3 receptor agonists
03/30/2005EP1518858A1 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
03/30/2005EP1518562A2 Dopamine transporter imaging agents
03/30/2005EP1518561A2 Dopamine transporter imaging agents
03/30/2005EP1518556A1 Therapeutic agent for brain hemorrhage
03/30/2005EP1518555A1 Analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
03/30/2005EP1518553A2 Use of nitrate ester compounds for treating pain or providing analgesia
03/30/2005EP1517989A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
03/30/2005EP1517914A2 9-alpha-substituted estratrienes as selectively active estrogen
03/30/2005EP1517912A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
03/30/2005EP1517909A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
03/30/2005EP1517908A2 Novel benzimidazole derivatives
03/30/2005EP1517907A2 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
03/30/2005EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
03/30/2005EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
03/30/2005EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
03/30/2005EP1517894A1 N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin antagonists and/or serotonin reuptake inhibitors
03/30/2005EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
03/30/2005EP1517708A1 Combination treatment for depression and anxiety by nk1 and nk3 antagonists
03/30/2005EP1517707A1 Treatment for depression and anxiety with the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent
03/30/2005EP1517695A2 Osteopontin, oligodendrocytes and myelination
03/30/2005EP1517689A2 Selective analgesic agents
03/30/2005EP1517688A2 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
03/30/2005EP1517686A2 Use of dantrolene, a ryanodine antagonist, in treating neural injury
03/30/2005EP1517685A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses
03/30/2005EP1517679A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
03/30/2005EP1517674A2 Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production
03/30/2005EP1517671A2 Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
03/30/2005EP1517667A2 Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
03/30/2005EP1450770B1 Pharmaceutical composition comprising a 5ht1 receptor agonist
03/30/2005EP1438289B1 Indole derivatives as cox ii inhibitors
03/30/2005EP1390037A4 Methods for treating delirium using glucocorticoid receptor-specific antagonists
03/30/2005EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders
03/30/2005EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists
03/30/2005EP1326616B1 Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder
03/30/2005EP1307182B1 Pharmaceutical composition for transdermal delivery of befloxatone
03/30/2005EP1250132B1 Ibuprofen containing active agent preparation
03/30/2005EP1242089B1 Use of adatanserin for the treatment of acute neurodegenerative disorders
03/30/2005EP1237898B1 N?6 heterocyclic 8-modified adenosine derivatives
03/30/2005EP1237551B1 Pharmaceutical formulations containing zolmitriptan
03/30/2005EP1224163B1 Use of carbonylamino derivatives against cns disorders
03/30/2005EP1194429B1 Potassium channel openers
03/30/2005EP1185294B1 Peptides for the treatment of impaired interpersonal and behavioral disorders
03/30/2005EP1091942B1 Potassium channel blocking agents
03/30/2005EP1087765B1 Use of optically pure (-) norcisapride in the treatment of irritable bowel syndrome
03/30/2005EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors
03/30/2005EP0758890B1 Use of no scavengers, inhibitors or antagonists in the treatment of migraine
03/30/2005CN1602425A Therapeutic and diagnostic uses of antibody specificity profiles
03/30/2005CN1602360A Methods of increasing endogenous erythropoietin (EPO)
03/30/2005CN1602358A Recombinant fusion proteins and the trimers thereof
03/30/2005CN1602311A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase
03/30/2005CN1602310A Benzothiazoles compound
1 ... 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 ... 1833